According to ImmunoGen 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 30.3331. At the end of 2023 the company had a P/S ratio of 13.7.
Year | P/S ratio | Change |
---|---|---|
2023 | 13.7 | 36.47% |
2022 | 10.1 | -56.95% |
2021 | 23.4 | 146.29% |
2020 | 9.49 | 1.9% |
2019 | 9.32 | -30.57% |
2018 | 13.4 | 82.73% |
2017 | 7.34 | 65.72% |
2016 | 4.43 | -78.65% |
2015 | 20.8 | 192.92% |
2014 | 7.08 | -57.08% |
2013 | 16.5 | -80.15% |
2012 | 83.2 | 105.47% |
2011 | 40.5 | -1.53% |
2010 | 41.1 | 70.95% |
2009 | 24.0 | 281.05% |
2008 | 6.31 | 40.15% |
2007 | 4.50 | -19.89% |
2006 | 5.62 | -14.58% |
2005 | 6.58 | -36.27% |
2004 | 10.3 | -40.27% |
2003 | 17.3 | 2.2% |
2002 | 16.9 | -86.3% |
2001 | 123 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 3.79 | -87.52% | ๐บ๐ธ USA |
Novartis NVS | 3.90 | -87.15% | ๐จ๐ญ Switzerland |
Pfizer PFE | 2.46 | -91.90% | ๐บ๐ธ USA |
Eli Lilly LLY | 20.4 | -32.71% | ๐บ๐ธ USA |
Amgen AMGN | 5.14 | -83.06% | ๐บ๐ธ USA |
Sanofi SNY | 2.44 | -91.96% | ๐ซ๐ท France |
Bristol-Myers Squibb BMY | 2.02 | -93.34% | ๐บ๐ธ USA |
Seagen
SGEN | 18.8 | -38.15% | ๐บ๐ธ USA |